Heiko Pohl
Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results.
Gantenbein A, Bonvin C, Kamm C, Schankin C, Zecca C, Zieglgänsberger D, Merki-Feld G, Pohl H, Rudolph N, Ryvlin P, Agosti R, Schäfer E, Meyer I, Kulartz-Schank M, Arzt M. Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results. J Neurol 2024
Jun 13, 2024Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results.
Jun 13, 2024J Neurol 2024
Gantenbein Andreas R, Bonvin Christophe, Kamm Christian Philipp, Schankin Christoph J, Zecca Chiara, Zieglgänsberger Dominik, Merki-Feld Gabriele Susanne, Pohl Heiko, Rudolph Nicole, Ryvlin Philippe, Agosti Reto, Schäfer Elisabeth, Meyer Ina, Kulartz-Schank Monika, Arzt Michael E
Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study
Gantenbein A, Agosti R, Gobbi C, Flügel D, Schankin C, Viceic D, Zecca C, Pohl H. Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study. Cephalalgia 2021; 41:1181-1186.
May 17, 2021Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study
May 17, 2021Cephalalgia 2021; 41:1181-1186
Gantenbein Andreas R, Agosti Reto, Gobbi Claudio, Flügel Dominique, Schankin Christoph J, Viceic Dragana, Zecca Chiara, Pohl Heiko